Business Wire

Mawi iSWAB Microbiome-EL Enables Prime Discoveries’ Development of Rapid Extraction-Less COVID Diagnostic Assay

Share

Mawi DNA Technologies (Mawi), a biotechnology company focusing on the development of innovative technologies for biosampling, announces that Prime Discoveries has successfully developed CovidDetect™, a rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2. Without the need for RNA extraction and purification, the sample result occurs in less than 30 minutes. The assay uses Mawi’s new iSWAB Microbiome-EL (Extraction-Less) sample collection technology. This allows RNA release from the sample and maintains stability, protecting it from degradation and allowing room temperature storage and transport.

Prime Discoveries recently received CE IVD marking for CovidDetect™and plans to pursue FDA 510K approval soon. Clinical results from Prime CovidDetect™ has been peer reviewed and recently published in PLOS ONE under “A Rapid, Specific, Extraction-Less, and Cost-Effective RT-LAMP Test for the Detection of SARS-CoV-2 in Clinical Specimens.” The CE marking allows deployment of a solution to countries in Africa and Asia where rapid, inexpensive diagnostics for various infections with minimal technical expertise and equipment infrastructure is highly required.

Prime CovidDetect™ leverages Mawi’s unique iSWAB Microbiome-EL sample collection buffer with Prime Discoveries’ patented Loop AMPlification (LAMP) technology. This allows isothermal nucleic acid amplification removing the need for expensive thermal cycling equipment required for PCR. The Extraction-Less protocol bypasses the expensive and complex nucleic acid extraction and purification step, saving 60-90 minutes of sample processing time needed for PCR.

Arun Manoharan, Ph.D., Chief Science Officer at Prime Discoveries, said, “The COVID pandemic has shown that there is a big need for rapid diagnostic assays. Prime Discoveries aims to build a portfolio of solutions which can provide results in under 45 minutes with minimal laboratory, reagent and technical skill requirements. This is ideal for point of care testing in rural neighborhoods, mobile testing, border points of entry and clinical locations with minimal infrastructure. Our work with COVID has shown stable performance of the Mawi iSWAB Microbiome-EL for hundreds of clinical samples with similar or superior performance to RT-PCR solutions. Samples have been stable for more than two weeks with minimal RNA degradation along with high compatibility with our isothermal nucleic acid amplification techniques.” He added, “Our partnership with Mawi enables Prime Discoveries to develop room temperature sampling with Extraction-Less capabilities for our rapid diagnostic solutions in many areas. These include influenza, chlamydia, gonorrhea, trichomonas, HBV, HCV, HPV, TB, herpes, syphilis, etc. We are excited to partner with Mawi for future products empowering customers to test thousands of patients rapidly for various infections including respiratory, gastrointestinal, sexually transmitted pathogens and those with anti-microbial resistance.”

About Prime Discoveries

Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Founded in NYC in 2017, Prime’s scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and New York University. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar (Bloomberg), Esther Dyson (23 & Me), BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others. For more information, visit www.primediscoveries.com.

About Mawi DNA Technologies

Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors:
Jerome David, VP of Sales and Marketing
510-256-5186, j.david@mawidna.com

Media Contact:
Susan Tellem, APR, RN, BSN
310-313-3444, susan@tellemgrodypr.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LG Chem Develops Advanced Plastic Product to Prevent Thermal Runaway in EV Batteries16.5.2022 07:00:00 CEST | Press release

LG Chem (KRX: 051910) today announced that it has developed a new plastic product for battery application that is capable of preventing the spread of flame in batteries, delivering the longest fire-resistance performance in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220515005002/en/ LG Chem has developed an advanced plastic product which prevents thermal runaway in EV batteries. (Photo: Business Wire) LG Chem’s flame-retardant engineering plastic product is able to prevent the spread of flames, thanks to the company’s proprietary technology and manufacturing methods. The new advanced flame barrier product created by LG Chem is a highly functional engineering plastic product made from various composites including polyphenylene oxide (PPO) and polyamide (PA) resin. “We are proud to present this new product, a significant milestone for us after more than 10 years of dedicated research to deliver innovation for ou

Envoy Gateway Makes Using Envoy Proxy Easier for Developers and Reverses Fragmentation16.5.2022 06:01:00 CEST | Press release

Members of the steering group for Envoy Gateway (EG), including Envoy creator Matt Klein and representatives from Ambassador Labs, Fidelity Investments, Tetrate, and VMware, Inc., today announced their joint commitment to the project, which launched today at KubeCon + CloudNativeCon, Europe 2022, under the auspices of the Cloud Native Computing Foundation® (CNCF®). Envoy Gateway is a new effort within the Envoy proxy open source project to simplify Envoy use in cloud-native application development. Envoy Gateway will reduce existing, redundant efforts around Envoy and make it much easier for application developers to use Envoy as a basic API gateway “out of the box” and as a Kubernetes Ingress controller. Exposing a simplified set of APIs, and implementing the Kubernetes Gateway API, EG makes it easier to extend Envoy. Developers will now have a cost-free, unfettered way to provide external access to their work in progress. At the same time, Envoy Gateway will not replace API managemen

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis15.5.2022 18:41:00 CEST | Press release

Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was published in The New England Journal of Medicine (NEJM). The promising 12-week data that showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF) will also be presented at the American Thoracic Society (ATS) International Conference Breaking News session on May 16 in San Francisco.1 “These encouraging, early data showed that treatment with BI 1015550 slowed the rate of lung function decline in patients who were not on approved antifibrotics, as well as those who were taking existing antifibrotic therapy,” commented Luca Richeldi, Professor of Respiratory Medicine at the Università Cattolica del Sacro Cuore in Rome, Italy, and the Principal Investigator on the trial. The primary endpoint of the trial was the change from baseline in forced vital capacity (FVC) – meaning the maximum amount of air (m

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202213.5.2022 13:24:00 CEST | Press release

Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2022. Since the beginning of the year, the Group has recorded a consolidated turnover amounting to €440.9 million, an increase of 25.1% compared to the corresponding data for 2021. All indicators are positive for the period. In the first quarter of 2022 the consolidated EBITDA was €70.9 million compared to €59.6 million in 2021, equal to 16.1% of the turnover. EBIT, from January to March, was €57.7 million (€47.9 million in 2021), and is equal to 13.1% of the turnover. The profit before tax, from January to March, was €59.4 million (€47.6 million in 2021), equal to 13.5% of the turnover. The net financial position of the Group on 31 March 2022 is also positive by 279.7 million. The net financial position on 31 December 2021 was positive for €193.2 million. The comparison with the figures recorded at the end of March 2020 is even sharper. Over the past 24 months, first-quarter turnover inc

Tecnotree Launches Total Digital Transformation Suite for Enterprises and Customers of MTN Ghana13.5.2022 12:00:00 CEST | Press release

Tecnotree, a Finnish-based global provider of digital transformation solutions for Communication Service Providers (CSPs) and Digital Service Providers (DSPs), announced the launch of its digital transformation stack, for enterprise and consumer businesses with MTN Ghana, one of the leading telecommunications service providers in Ghana with over 25.3 million subscribers. This transformation for B2B and B2C empowers the operator with rapid response capabilities, allowing it to meet its enterprise market demand and deliver augmented customer experiences at a reduced cost. Tecnotree’s Digital Transformation Suite 5 product stack is completely TM Forum compliant and deploys a micro-services-based architecture with built-in features for price approvals and overriding, on-boarding and monitoring of cash flow orders via the Customer 360 view, enabling self-care features for consumers and enterprises to manage their accounts, monitor onboarding, raise tickets and service requests. In addition,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom